Gao SG, Jia RN, Feng XS, Xie XH, Shan TY, Pan LX, Song NS, Wang YF, Ding KL, Wang LD. Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma. World J Gastroenterol 2011; 17(47): 5221-5226 [PMID: 22215948 DOI: 10.3748/wjg.v17.i47.5221]
Corresponding Author of This Article
Dr. Xiao-Shan Feng, First Affiliated Hospital, Cancer Institute, Henan University of Science and Technology, Luoyang 471003, Henan Province, China. samfeng137@hotmail.com
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
She-Gan Gao, Rui-Nuo Jia, Xiao-Shan Feng, Xuan-Hu Xie, Tan-You Shan, Li-Xian Pan, Na-Sha Song, Yu-Feng Wang, Kai-Li Ding, Department of Oncology, First Affiliated Hospital, Cancer Institute, Henan University of Science and Technology, Luoyang 471003, Henan Province, China
Li-Dong Wang, Henan Key Laboratory for Esophageal Cancer, Laboratory for Cancer Research, Basic Medical College, Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: Gao SG and Feng XS designed the study; Jia RN, Xie XH, Shan TY, Pan LX, Song NS, Wang YF and Ding KL performed the research; Gao SG and Jia RN carried out the analyses and wrote the article; Feng XS, Gao SG and Wang LD approved the final version of the manuscript.
Supported by The National Outstanding Young Scientist Award of China, No. 30025016; State Key Project for Basic Research, No. 30670956; and the Natural Science Foundation of Henan Province, China, No. 0511043200
Correspondence to: Dr. Xiao-Shan Feng, First Affiliated Hospital, Cancer Institute, Henan University of Science and Technology, Luoyang 471003, Henan Province, China. samfeng137@hotmail.com
Telephone: +86-379-64820811 Fax: +86-379-64820811
Received: February 5, 2011 Revised: March 29, 2011 Accepted: April 5, 2011 Published online: December 21, 2011
Abstract
AIM: To evaluate the effects and safety of combination chemotherapy with oxaliplatin (L-OHP) and S-1 (SOX regimen) in older patients with advanced gastric cardiac adenocarcinoma (GCA).
METHODS: Seventy patients with advanced GCA were classified according to age into an older group (≥ 75 years) and a control group (< 75 years). The SOX regimen was administered to the two groups as follows: S-1 (40 mg/m2 po bid) on days 1 to 14 followed by a 7-d off period, plus L-OHP (65 mg/m2 iv) for 2 h on days 1 and 8 of a 21-d cycle. This regimen was repeated for four to six cycles. Response and swallow statuses were evaluated after two cycles (6 wk). Effects and toxicity were evaluated four weeks after chemotherapy was completed.
RESULTS: The response rate was 65.6% (21/32) in the older group and 68.4% (26/38) in the control group (χ2 = 0.062 and P = 0.804). Improvement in swallowing was 78.1% (25/32) in the older group and 76.3% (29/38) in the control group (χ2 = 0.032 and P = 0.857). Efficacy was 68.8% (22/32) in the older group and 65.8% (25/38) in the control group (χ2 = 0.069 and P = 0.793). Toxicities were reversible and similar in both groups (P > 0.05).
CONCLUSION: The SOX regimen is an effective, safe and well-tolerated regimen for older patients with advanced GCA.
